Gabapentin and metformin
Pro Research Analysisby 
Searched over 200M research papers
Gabapentin and Metformin: Therapeutic Effects and Applications
Introduction to Gabapentin and Metformin
Gabapentin and metformin are two widely used medications with distinct primary indications. Gabapentin is primarily prescribed for neuropathic pain and as an adjunct therapy for partial seizures, while metformin is a first-line treatment for type II diabetes. Recent research has explored their potential applications beyond their primary uses, including their effects on pain management and cancer treatment.
Gabapentin and Metformin in Pain Management
Neuropathic Pain and Cognitive Impairments
Neuropathic pain often leads to cognitive deficits, which are inadequately addressed by existing therapeutics. A study on mice with neuropathic pain revealed that gabapentin, while providing pain relief, worsened cognitive impairments and did not reverse structural changes in the brain associated with pain2. In contrast, metformin not only alleviated pain but also reversed cognitive impairments and restored structural integrity in the brain, suggesting its potential repurposing for treating neuropathic pain and its cognitive comorbidities2.
Radiation Dermatitis and Pathological Pain
In a study on mice with radiation dermatitis, both gabapentin and metformin were found to alleviate pathological pain. However, metformin showed a significant reduction in inflammatory markers and signaling pathways associated with pain, such as p38MAPK and NF-κB, indicating a more profound anti-inflammatory effect compared to gabapentin1. This suggests that metformin might offer additional benefits in managing pain through its anti-inflammatory properties.
Metformin in Cancer Treatment
Triple-Negative Breast Cancer
Metformin has shown promising anti-tumor effects in various cancers, including triple-negative breast cancer. A novel metformin derivative, HL010183, demonstrated significantly higher potency in inhibiting the proliferation and invasion of triple-negative breast cancer cells compared to metformin alone. This derivative also showed comparable efficacy in reducing tumor growth in vivo at lower doses, highlighting its potential as a more effective treatment option for aggressive breast cancers3.
Pharmacokinetics and Analytical Methods
Quantification in Biological Samples
Accurate quantification of gabapentin and metformin in biological samples is crucial for pharmacokinetic studies and therapeutic monitoring. Advanced methods using hydrophilic interaction liquid chromatography-tandem mass spectrometry (HILIC-MS/MS) have been developed for this purpose. These methods offer high sensitivity and specificity, allowing for the precise measurement of these drugs in human plasma and wastewater samples4 5 6. Such analytical techniques are essential for ensuring the efficacy and safety of these medications in clinical settings.
Adverse Effects and Safety Considerations
Gabapentin Toxicity
Gabapentin toxicity can occur in patients with impaired renal function, leading to severe symptoms such as coma, myoclonus, and altered mental status. A case study reported reversible hearing loss and confusion in a patient with acute renal failure, which resolved after discontinuation of gabapentin and hemodialysis. This underscores the importance of monitoring renal function and adjusting dosages accordingly to prevent toxicity7.
Conclusion
Gabapentin and metformin have demonstrated significant potential beyond their primary indications, particularly in pain management and cancer treatment. While gabapentin is effective for neuropathic pain, metformin offers additional benefits in reducing cognitive impairments and inflammation. Moreover, novel metformin derivatives show promise in treating aggressive cancers. Advanced analytical methods ensure accurate monitoring of these drugs, enhancing their therapeutic efficacy and safety. Further research is warranted to fully explore and optimize their applications in various medical conditions.
Sources and full results
Most relevant research papers on this topic
[Metformin alleviates pathologic pain in mice with radiation dermatitis by inhibiting p38MAPK/NF-κB signaling pathway].
Metformin significantly alleviates pathological pain symptoms in mice with radiation dermatitis, possibly by inhibiting the activation of the p38MAPK/NF-B signaling pathway.
RCT
Animal StudyNeuropathic Pain Creates an Enduring Prefrontal Cortex Dysfunction Corrected by the Type II Diabetic Drug Metformin But Not by Gabapentin
Metformin effectively reverses cognitive impairments in male mice with neuropathic pain, suggesting it can be repurposed for treating pain and its cognitive comorbidities.
Non-RCTAnimal Study
Very Rigorous JournalA novel metformin derivative, HL010183, inhibits proliferation and invasion of triple-negative breast cancer cells.
The novel metformin derivative HL010183 shows a 100-fold more potent inhibitory effect on triple-negative breast cancer cell proliferation and invasiveness than metformin, offering potential for a new treatment strategy.
In Vitro StudyDevelopment and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometry method for the quantification of the antidiabetic drug metformin and six others pharmaceuticals in wastewater.
The developed HILIC-tandem mass spectrometry method effectively quantifies metformin and six other pharmaceuticals in wastewater, with low limits of quantification for both influent and effluent samples.
Determination of gabapentin in human plasma using hydrophilic interaction liquid chromatography with tandem mass spectrometry.
This study developed a rapid, sensitive, and selective method for determining gabapentin in human plasma using hydrophilic interaction liquid chromatography/tandem mass spectrometry, successfully applied to a bioequivalence study.
Validated LC-MS-MS method for the determination of gabapentin in human plasma: application to a bioequivalence study.
The developed LC-MS-MS method is a specific, sensitive, accurate, and precise method for determining gabapentin in human plasma, with potential applications in bioequivalence studies.
A probable case of gabapentin-related reversible hearing loss in a patient with acute renal failure.
Gabapentin-related hearing loss, myoclonus, and confusion in a patient with acute renal failure rapidly improved after hemodialysis and discontinuing the medication.
Case ReportMetformin produces anxiolytic‐like effects in rats by facilitating GABAA receptor trafficking to membrane
Metformin shows potential in treating anxiety disorders by facilitating GABAA receptor trafficking, offering a potential alternative to benzodiazepines.
Rigorous JournalMetformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug
Metformin alters the gut microbiome in individuals with treatment-naive type 2 diabetes, contributing to its therapeutic effects and improving glucose tolerance.
RCTVery Rigorous Journal
Highly CitedQuantifying the Effect of Metformin Treatment and Dose on Glycemic Control
Metformin effectively lowers HbA1c levels in diabetic patients, and higher doses can potentially maximize glycemic control without increasing gastrointestinal effects.
Meta-AnalysisVery Rigorous JournalHighly Cited